Who Owns CVS Pharmacy?

CVS Pharmacy's sustainability practices are governed by CVS Health's corporate responsibility framework. CVS Health has committed to achieving carbon neutrality across its operations by 2040 and has set a target to reduce absolute Scope 1 and 2 emissions by 50% by 2030 from a 2019 baseline.

CVS Health reports that it has invested in energy efficiency improvements across its retail locations, including LED lighting conversions and energy-efficient HVAC systems. The company has installed solar panels at select store locations and distribution centers. CVS Health's 2024 ESG report indicates progress toward its emission reduction targets, though the company has not disclosed specific store-level sustainability metrics for CVS Pharmacy.

CVS Pharmacy operates medication take-back programs at its retail locations, providing safe disposal options for unused medications. The company also maintains responsible sourcing policies for pharmaceutical products and retail merchandise, requiring supplier compliance with environmental and ethical standards.

CVS Health's decision to stop selling tobacco products in 2014 remains one of the most significant public health initiatives by a retail pharmacy chain. The company has also implemented restrictions on the sale of certain tobacco-adjacent products and has expanded its health and wellness product offerings.

CVS Pharmacy is not independently certified by any sustainability certification body specific to the retail pharmacy brand. The sustainability initiatives described above are corporate-level programs operated by CVS Health. Consumers seeking independently verified sustainability information should consult CVS Health's annual ESG report.

CVS Pharmacy's most significant recognition relates to its 2014 decision to stop selling tobacco products in all retail locations. The company received the Surgeon General's Medallion Award from the U.S. Surgeon General in 2014 for this decision, which was praised by the American Medical Association, the American Cancer Society, and other public health organizations.

CVS Health has been included on the Dow Jones Sustainability Index for North America in multiple years, though this recognition applies to the corporate entity rather than the CVS Pharmacy brand specifically.

No independent "best pharmacy" rankings from Consumer Reports, J.D. Power, or similar consumer research organizations have been publicly documented for CVS Pharmacy as a brand in recent years. Individual CVS Pharmacy locations and pharmacists have received state-level pharmacy practice awards, but these are not brand-level recognitions.

CVS Pharmacy has faced significant controversies related to the opioid crisis, pharmacy staffing, and regulatory compliance.

Opioid Crisis Settlements: CVS Pharmacy, along with other major pharmacy chains, has faced extensive litigation related to its role in dispensing opioid pain medications. In 2022, CVS Health agreed to a settlement worth approximately $5 billion over 10 years to resolve opioid-related claims with states, municipalities, and Native American tribes. The settlement resolved allegations that CVS failed to adequately monitor suspicious opioid prescriptions. In 2023, a federal jury in Cleveland found CVS Pharmacy, Walgreens, and Walmart liable for contributing to the opioid crisis in two Ohio counties, though the damages awarded were significantly less than plaintiffs sought.

DEA Controlled Substance Violations: CVS Pharmacy has faced regulatory action from the Drug Enforcement Administration (DEA) related to controlled substance dispensing. In 2012, two CVS Pharmacy stores in Sanford, Florida had their DEA registrations revoked for allegedly dispensing excessive quantities of oxycodone. CVS paid a $500,000 fine and agreed to compliance measures. The company has since implemented enhanced controlled substance monitoring programs across its pharmacy network.

Pharmacy Staffing and Prescription Errors: CVS Pharmacy has faced criticism regarding pharmacy staffing levels, with pharmacists and pharmacy technicians reporting high workloads that may contribute to prescription errors. A 2019 investigation by USA Today found that CVS Pharmacy and other chains had experienced an increase in prescription errors linked to staffing cuts and increased prescription volumes. CVS Health has stated that it has invested in staffing and technology to address these concerns, though pharmacy worker advocacy groups continue to raise concerns about working conditions.

HIPAA Violations: CVS Pharmacy has been subject to HIPAA enforcement actions. In 2017, CVS agreed to pay $500,000 to the State of New Jersey to settle allegations that it improperly disposed of patient information in trash dumpsters. The company has also faced individual HIPAA complaints related to pharmacy privacy practices, which are investigated by the HHS Office for Civil Rights.

Medicare and Medicaid Fraud: CVS Health has paid multiple settlements related to Medicare and Medicaid fraud allegations. In 2018, CVS subsidiary Omnicare agreed to pay $8 million to resolve allegations that it submitted false claims to Medicare for outdated prescription drugs. In 2022, CVS Caremark agreed to pay $6.5 million to settle allegations that it overcharged Medicare Part D for prescription drugs.

Aetna Medicare Advantage Challenges: Since the 2018 acquisition, CVS Health's Aetna Medicare Advantage business has faced significant challenges. In 2024, CVS Health reported elevated medical cost ratios in its Medicare Advantage plans, leading to a significant decline in the company's stock price. The Centers for Medicare and Medicaid Services (CMS) downgraded Aetna's star ratings for 2025, which affects bonus payments and enrollment. These challenges have created pressure on CVS Health's overall financial performance and have led to leadership changes.